Aims-Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. Methods-Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bcl-2 overexpression by immunohistochemistry.
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Aims-Apoptosis in prostate cancer was evaluated after three months of combined endocrine therapy to investigate the association with tumour grade, tumour stage, and the immunohistochemical detection of p53 and bcl-2 in tumour cells before and after therapy. Methods-Twenty six formalin fixed, paraffin wax embedded core biopsies and corresponding prostatectomy specimens, excised after three months of combined endocrine therapy, were analysed for the presence of apoptotic cells by the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, and for p53 and bcl-2 overexpression by immunohistochemistry. Results-All 26 adenocarcinomas were clinically localised at diagnosis. In biopsies performed before combined endocrine therapy, the apoptotic indices varied between 0.09% and 1.73%, while the tumour grade fell between Gleason score 1 and 8. The mean (SD) apoptotic count pretherapy was 0.71% (0.50). There was a significant association between elevated apoptotic counts and higher Gleason scores in the biopsies (p = 0.005). After three months of therapy, the percentage of apoptotic tumour cells increased independently of tumour stage, while a significant association with Gleason grade was found (p = 0.0018) and all the tumours had Gleason scores of < 7. In eight cases the apoptotic index was more than twice its pretherapy value. The remaining tumours showed less of an increase in the apoptotic index (five cases) or a reduction in the percentage of apoptotic cells. The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8).
Immunoreactivity to p53 was absent in all cases, before and after therapy, while a slight increase in the number of cells overexpressing bcl-2 was observed in five of the 13 tumours (38.1%) with reduced apoptotic indices after therapy. Conclusions-After three months of combined endocrine treatment a minority of clinically localised prostate neoplasms showed regressive epithelial alterations, associated with an increase in apoptotic tumour cells; an increase in cells overexpressing bcl-2 was observed in five of the 13 tumours with reduced apoptotic indices. (7 Clin Pathol 1997; 50:384-388) Keywords: apoptosis; nick end labelling; prostatic cancer Combination therapy using a nonsteroidal antiandrogen in association with a luteinising hormone releasing hormone (LHRH) agonist has significant benefits in both advanced and localised prostate cancer; some authors believe neoadjuvant total androgen withdrawal to have some beneficial effects as downstaging, while others reported that the majority of patients with locally advanced prostate carcinoma continue to have extraprostatic carcinoma despite clinical evidence suggestive of downstaging.IA Histological changes are commonly observed some months after combined endocrine therapy: a decrease in tumour size, vacuolisation of the cytoplasm, and changes in glandular size, the cell proliferation rate, and nuclear and nucleolar size are the most frequent. In vivo studies have identified apoptosis as the molecular event underlying the regression of androgen dependent human prostatic tumours after androgen ablation.5 Indeed, the histological appearance of apoptotic bodies is a characteristic early event6 that precedes the dramatic reduction in tumour volume observed after three months of combined endocrine therapy.7
The present study investigated the frequency of apoptosis, using the terminal deoxynucleotidyl transferase mediated dUTP-biotin nick end labelling (TUNEL) method, in 26 clinically localised prostatic carcinomas obtained by radical prostatectomy after three months of therapy with an LHRH agonist leuprorelin ( Each patient had a clinical stage B cancer and underwent a radical prostatectomy: before surgery all patients had received combined treatment with leuprorelin (3.75 mg per month subcutaneously) and flutamide (250 mg orally three times a day) for three months. The histopathological material was 26 ultrasound guided core biopsies performed before the combined endocrine therapy, and the subsequent prostatectomies. Further biopsies were not performed before radical prostatectomy, according to the protocol of neoadjuvant therapy. The biopsies were routinely processed. Grade was assigned using the Gleason system in which five distinct histological patterns are recognised.8 The radical prostatectomy specimens were cut into slices -0.5 cm thick from the apex to the base of the prostate and then fixed for 24 hours in formalin and embedded in paraffin wax.
LABELLING OF APOPTOTIC CELLS
The TUNEL method described by Gavrieli et al was used for apoptotic cell labelling.9 Thus, after deparaffinisation, sections were incubated with 20 ig/ml proteinase K for 15 minutes at room temperature and thoroughly washed in sterile distilled water. A rinse in terminal deoxynucleotidyl transferase (TdT) buffer (30 mM Trizma base, pH 7.2, 140 mM sodium cacodylate, 1 mM cobalt chloride) was performed before immersing the slides in a mixture ofTdT (0.3 units/,l) and biotin dUTP (0.03 nmols/,ul) in TdT buffer for 90 minutes at 37°C in a humidity chamber. Sections were rinsed in sterile distilled water, immersed in a 2% aqueous solution of bovine serum albumin (BSA) for 10 minutes at room temperature, rinsed in 0.05 M Tris buffered saline (TBS), pH 7.4, and covered with alkaline phosphatase conjugated streptavidin (1:30) for 30 minutes at room temperature. After visualisation of the reaction using new fuchsin, slides were slightly counterstained with haematoxylin and mounted.
IMMUNOHISTOCHEMISTRY
Immunohistochemical studies were performed using the peroxidase conjugated streptavidinbiotin complex method. The mouse monoclonal antibody to p53 protein (Mab D07, Novocastra Laboratories, Newcastle upon Tyne, UK) and the mouse anti-bcl-2 (clone 124 Dakopatts, Glostrup, Denmark), were used, diluted 1:100 and 1:40, respectively. A threshold of 5% immunoreactive tumour cells was chosen for the evaluation of p53 overexpression. Immunostaining for bcl-2 was assessed semiquantitatively, based on the proportion of immunoreactive tumour cells; cases were divided into negative (0%), and those with < 5% or > 5% immunoreactive cells.
QUANTITATION OF APOPTOTIC CELLS
The percentages of apoptotic cells (apoptotic index = number of TUNEL positive cells per 100 cells) were determined by counting 1000 tumour cells in randomly chosen areas of biopsy sections on a light microscope at x40 magnification. On the sections obtained after radical prostatectomy, the apoptotic index was determined by randomly counting 3000 tumour cells per patient.
STATISTICS
The significance of the associations was determined using the X2 test. The Mantel-Haenszel x2 test for linear association assessed the significance of trends. A value of p < 0.05 was considered statistically significant.
Results
All 26 patients included in the present study were submitted to preoperative combined endocrine therapy. Patients' ages ranged from 59 to 72 years (median 67.3). Tumours were categorised according to the final pathological stage: seven patients were classified as stage pT2a, six as stage pT2b, seven as stage pT2c, four as stage pT3a, and two as stage pT3c. Only one case, at stage pT3a, revealed a metastasis in the pelvic lymphnodal station.
In the haematoxylin and eosin preparations of radical prostatectomy, we found an almost even prevalence of some histopathological changes: non-tumoural prostatic tissue showed cell vacuolisation with smaller nucleoli, and prominence and hyperplasia of basal cells; adenocarcinoma showed decreased intraluminal crystalloids and areas of individual tumour cells, separated by abundant connective tissue, showing inconspicuous nucleoli and cytoplasmic vacuolisation.
For the evaluation of apoptosis, we compared TUNEL treated sections with haematoxylin and eosin stained sections. In each case, cells with the morphological characteristics of apoptosis were identified: chromatin condensation, formation of crescentic caps of condensed chromatin at the nuclear periphery, and formation of apoptotic bodies were visible in both biopsy and prostatectomy specimens, in the intercellular space as well as in the lumen, sometimes ingested by macrophages. As shown in table 1 the apoptotic count in 1000 tumour nuclei evaluated by the TUNEL method on biopsy samples varied considerably (mean (SD) 0.718 (0.50); range 0.09-1.73%). The mean apoptotic index in 3000 tumour nuclei after therapy was 0.75 (Q.51) (range 0.097-2.10%). The overall moderate increase in apoptotic index after combined endocrine therapy was not statistically significant (p = 0.8). However, two subgroups of patients with different apoptotic counts were recognised: the first had a twofold, or greater, increase in the apoptotic index after combined endocrine therapy; in the second group, however, the increase in the apoptotic index was less than twofold and in some cases there was even a decrease in the apotopic index after therapy.
HIGH APOPTOPIC INDEX INCREASE GROUP
Eight patients showed a twofold, or greater, increase in apoptopic index after combined endocrine therapy. This group contained Gleason grade 4-6 tumours, with a pretherapy apoptopic index oscillating between 0.091 and according to the age of patient. Low apoptotic counts before endocrine therapy were significantly associated with an increase in apoptosis after treatment (Mantel-Haenszsel test for linear association, p = 0.001).
Discussion
Previous work concerning the evaluation of apoptosis in vitro has shown that the time window during which the morphological changes due to programmed cell death occur is relatively short (between 30 minutes and two hours); thus, many cells in the early stages of apoptosis may escape detection in vivo.10 The TUNEL method is based on direct, specific, in situ labelling of DNA breaks in the nuclei. Gorczyca and coworkers applied this method to human solid tumours sampled by fine needle biopsy, and reported that the apoptotic phase characterised by the presence of DNA strand breaks, which precedes the gross changes in cell morphology, is very long.11 The TUNEL technique labels the small (< 2 gm) apoptotic bodies as well as the classical crescentic caps of condensed chromatin at the nuclear periphery,'2 thus avoiding confusion with other cells that have condensed chromatin, such as telophase mitotic cells or polymorphic granulocytes (fig 1) . Furthermore, this technique allows one to differentiate the condensed chromatin of apoptotic nuclei from the nuclei of lymphocytes that diffusely infiltrate prostate adenocarcinomas after combined endocrine therapy. Therefore, according to Gavrieli and coworkers,9 by detecting DNA fragmentation that occurs before the appearance of morphological features, the TUNEL method is a highly sensitive technique that "enables a determination of the actual fraction of cells undergoing programmed cell death". The presence of apoptosis after combined endocrine therapy is a well known phenomenon,7 13 In conclusion, the TUNEL method is a useful tool for the evaluation of different apoptotic counts in prostatic cancer after combined endocrine therapy, particularly as it demonstrated differences between the behaviour of low Gleason grade (% 6) cancers, confined to the organ, and confined or locally advanced higher Gleason grade (¢ 6) cancers.
